We examined, in conscious dogs, the effects of /?-adrenergic stimulation on measurements of left circumflex coronary arterial diameter and blood flow and on calculations of late diastolic coronary resistance (LDCR) and left circumflex coronary internal cross-sectional area (CSA). Isoproterenol (0.1 fig/kg) initially decreased mean arterial pressure by 25 ± 2% (mean ± SEM), and LDCR by 62 ± 4%, and increased heart rate by 82 ± 10%, left ventricular (LV) dP/dt by 79 ± 12%, and mean coronary blood flow by 85 ± 5%, while CSA rose slightly. The peak effects on CSA (24 ± 2%) occurred later, along with decreases in mean arterial pressure (7.4 ± 1.0%) and LDCR (25 ± 5.3%) and increases in coronary blood flow (14 ± 2%), LV dP/dt (12 ± 3%), and heart rate (24 ± 4%). Pirbuterol (1.0 jug/kg) induced changes that were qualitatively similar to those induced by isoproterenol. Prenalterol (20 /xg/kg), a cardioselective /?i-adrenergic receptor agonist, did not affect mean arterial pressure, but increased heart rate by 40 ± 5%, LV dP/dt by 72 ± 10%, mean coronary blood flow by 34 ± 11%, and CSA by 26 ± 3%, and decreased LDCR by 29 ± 5%. Isoproterenol and pirbuterol, but not prenalterol, increased coronary sinus Oj content and decreased A-V O> difference. After /?i-adrenergic receptor blockade with atenolol (1 mg/kg), prenalterol no longer induced significant effects, whereas isoproterenol and pirbuterol decreased mean arterial pressure similarly to what was observed prior to blockade, but did not increase LV dP/dt, and induced attenuated increases in mean coronary blood flow, CSA, and decreases in LDCR. Thus, in the intact, conscious animal, large coronary arteries are regulated by /J-adrenergic mechanisms. Surprisingly, a major fraction of large coronary arterial dilation appeared to be either directly or indirectly due to fi\adrenergic receptor mechanisms, although /? 2 -adrenergic effects were also significant. (C/rc Res 51:
56
THERE are two major mechanisms by which fi-adrenergic receptor stimulation dilates resistance vessels in the coronary circulation: (1) direct stimulation of vascular receptors and (2) metabolic dilation secondary to increases in myocardial metabolic demands (Berne and Rubio, 1979; Parratt, 1980) . Whereas it is well recognized that coronary vessels contain fi-adrenergic receptors (Berne and Rubio, 1979; Parratt, 1980; Klocke et al., 1965; Zuberbuhler and Bohr, 1965) , it is not clear whether these receptors in the large coronary arteries are of the fi\ or fi> subtypes. It is now well established that coronary resistance vessels have fit receptors (Ross and Jorgensen, 1970; Adam et al., 1970; McRaven et al., 1971; Mark et al., 1972; Gross and Feigl, 1975) . Although studies in isolated coronary vessel preparations have suggested that the receptors of large coronary arteries are of the fix type (Baron et al., 1972; De La Lande et al., 1974; Drew and Levy, 1972; Johannson, 1973) , no in vivo studies on large coronary arteries have been carried out.
The goal of the present investigation was to test the hypothesis that large coronary arteries are regulated by /?i-adrenergic mechanisms and to determine for the first time, using direct and continuous measurements, the extent to which activation of /Si-and / ?•_>adrenergic receptors elicited vasodilation of large and small coronary vessels in conscious dogs. This was accomplished by administering isoproterenol, an agent which contains fi\-and /62-adrenergic properties, and pirbuterol, an agent which is thought to contain primarily /?2-adrenergic properties (Moore et al., 1978) , in the presence and absence of selective fi\adrenergic receptor blockade. Furthermore, selective /?i-adrenergic stimulation was accomplished with prenalterol, which does not possess /^-stimulating properties . It was considered important to study this in conscious dogs, since anesthesia modifies autonomic control of the circulation (Vatner and Braunwald, 1975) , as well as vascular reactivity (Altura and Altura, 1975) .
Methods
Mongrel dogs were anesthetized with pentobarbital Na, 30 mg/kg. Transducers were implanted through a thoracotomy in the 5th left intercostal space. Two miniature 7 MHz ultrasonic transducers (2 X I mm, 12 mg) were implanted on opposing surfaces of the left circumflex coronary artery, 3-6 cm from its origin in 14 dogs. The ultrasonic transducers were covered with Insl-X (Insl-X Products Corp.) and attached to a Dacron (Dupont, de Nemours & Co., Inc.) backing. The Dacron was sutured to the outer adventitia of the coronary artery using Ethicon 6-0 suture (Ethicon, Inc.). An electromagnetic (n = 4) or Doppler (n = 8) flow transducer was implanted distally on the same vessel in 12 dogs. Pacing electrodes were implanted on the right atrium. In all dogs, miniature pressure gauges (Konigsberg Instruments, Inc.) were implanted in the left ventricle and descending thoracic aorta and heparin-filled Tygon (Norton Co., Plastics and Synthetics Div.) catheters were implanted in the left atrium and descending thoracic aorta. In seven dogs, coronary sinus catheters were implanted at a subsequent operation through a right thoracotomy approach after general anesthesia with pentobarbital Na, 25 mg/kg. Left ventricular (LV) pressure was measured with the implanted miniature gauge, which was calibrated in vitro with a mercury manometer and cross-calibrated in vivo with measurements of pressure from the aortic and left atrial catheters. Coronary blood flow was measured with a Benton square wave electromagnetic flowmeter (Benton Instruments), or a Doppler ultrasonic flowmeter. Phasic coronary arterial diameter was measured instantaneously and continously with an improved ultrasonic dimension gauge (Patrick et al., 1974; Pagani et al., 1978; Vatner et al., 1980; Macho et al., 1981) . The frequency response of the dimension gauge is flat to 100 Hz. The drift of the instrument is minimal, i.e., less than 0.01 mm in 6 hours. To further ensure data reliability, repeated calibration references were obtained regularly throughout the experiments, and the received ultrasonic signal was monitored continously on an oscilloscope. Any major changes in alignment of the crystals was detected in the received signal and invalidated the experiment.
The experiments were conducted 1-3 weeks after operation in healthy conscious dogs lying quietly. Measurements of left circumflex coronary arterial diameter, aortic root pressure, LV pressure, LV dP/dt, LV diameter, left atrial pressure, left circumflex coronary blood flow, and heart rate were recorded continuously during control and interventions. The various interventions were carried out on different experimental days. Combined /3i-and /?.>-adrenergic receptor stimulation was accomplished with iv bolus doses of isoproterenol, 0.01, 0.1, and 0.5 jug/kg in seven dogs. Bolus doses of pirbuterol, 0.1 and 1.0 jug/kg, were also administered iv. The l.Ojug/kg dose was selected to compare with the isoproterenol dose of 0.1 jug/kg, since pilot studies in which dose-response curves were examined demonstrated similar reductions in arterial pressure with these doses of the two drugs. After recovery from isoproterenol and pirbuterol, /?i-adrenergic receptor blockade was accomplished with iv atenolol (1.0 mg/kg), and isoproterenol (0.1 and 0.5 jug/kg) and pirbuterol (1.0 /xg/kg) were administered again. The dose of atenolol was selected on the basis of its ability to block inotropic responses to isoproterenol without blocking peripheral vasodilator responses to isoproterenol. Singh et al. (1975) showed that atenolol, 0.5 mg/kg, does not block the inotropic response to isoproterenol, 0.4 /xg/kg. We previously demonstrated that atenolol, 1.0 mg/kg, blocks /?,-adrenergic effects of isoproterenol but not the vasodilation induced by the the drug in the limb . This was further tested in this study in two additional dogs instrumented with electromagnetic flow probes on the right iliac artery and pretreated with hexamethonium, 35 mg/kg, to block reflex effects. Isoproterenol, 0.1 /ig/kg, reduced iliac vascular resistance by 71.4 and 70.4%, respectively, in these two dogs prior to atenolol, 1 mg/kg, and by 71.9 and 72.6%, respectively, after atenolol, 1 mg/kg. Thus, atenolol, 1 mg/ kg, appears to block effectively the inotropic but not peripheral vasodilator responses to isoproterenol. In five dogs, atropine (0.1 mg/kg) was administered after /?i-adrenergic receptor blockade, and isoproterenol (0.1 and 0.5 jug/kg) and pirbuterol (1.0 fig/kg) were injected again. Then isoproterenol and pirbuterol were administered after combined 57 /?i-and /? L .-adrenergic receptor blockades with propranolol, 1 mg/kg. In seven dogs, isoproterenol was infused iv at a dose of 0.1. jug/kg per min for 7 minutes before and after selective /3,-adrenergic receptor blockade and with heart rate held constant. Selective /?i-adrenergic receptor stimulation was accomplished with prenalterol, 4.0jug/kg per min X 5 min, for a total dose of 20 fig/kg, iv, in seven dogs. Due to the long half life of prenalterol , it was administered on separate days in the presence and absence of selective /?i-adrenergic receptor blockade. In the seven dogs with coronary sinus catheters, experiments were conducted 1 week postoperatively, and samples of arterial and coronary sinus blood were drawn prior to and during peak responses to isoproterenol, pirbuterol, and prenalterol. Arterial and coronary sinus O> contents were measured using a LEX Oj CON-K oximeter (Lexington Instruments). The effects of isoproterenol and pirbuterol were also compared in five conscious dogs where reflex effects were eliminated by pretreating the dogs with chronic reserpine (0.25 mg/kg X 4 days), and atropine 0.1 mg/kg. In these experiments heart rate, mean arterial pressure, and LV dP/ dt were assessed. At a terminal experiment, the left circumflex coronary artery was cannulated and pressure was raised and lowered by changing the level of a blood reservoir. Left circumflex coronary diameter changed directionally with arterial pressure, as long as no vasoactive agents were introduced.
The data were recorded on a 14-channel tape recorder (Bell & Howell Co., Datatape Div.) and played back on two multichannel oscillographs (Gould-Brush). Mean pressures, coronary diameters, and blood flows were assessed using RC filters with 2-second time constants. LV dP/dt was derived by differentiating the LV pressure signal with a Philbrick operational amplifier (Teledyne Philbrick) with a frequently response of 700 Hz connected as a differentiator. A triangular wave signal with known slope (rate of change) was substituted for the pressure signal to calibrate the differentiator directly. Heart rate was measured continuously with a cardiotachometer triggered by the LV pressure pulse. While external coronary diameter was measured continuously, the internal radius was calculated by determining at autopsy the mass of a coronary artery with known length from the point at which the piezoelectric crystals were located. Thus, wall volume could be calculated as the quotient of mass and density (d = 1.06 g/cm'). After the wall volume, one wall thickness value, and external diameter were known, the internal changing diameter was calculated.
Late diastolic coronary resistance, which reflects primarily small coronary vessel resistance, was calculated as the quotient of late diastolic arterial pressure and late diastolic coronary blood flow. Mean ± SEM were calculated for all variables. Data were analyzed before and after autonomic blockade using Student's f-test for paired comparisons (Armitage, 1973) . To adjust for the increased incidence of Type 1 errors consequent to double comparisons, the critical probability level was computed by the Bonferroni method (Miller, 1966) , as the ratio of a/k, where a equals the error rate (P < 0.05) and k equals the number of tests (n = 2). Thus, the critical probability level of P < 0.025 was utilized, when more than one comparison was examined.
Results
Control values and absolute changes from control are noted in the tables, while data are presented as percent change from control in the text and figures. Statistically significant responses are noted in figures and tables. Mean coronary blood flow, late diastolic iv. Data from responses to isoproterenol 0.1 and 0.5 coronary resistance (LDCR), mean external coronary /xg/kg, iv before and after selective /?i-adrenergic diameter, and internal coronary cross-sectional area blockade are included in Tables 1 and 2. The peak (CSA) refer to the left circumflex coronary artery. effects of isoproterenol on mean arterial pressure, coronary blood flow, LDCR, LV dP/dt and heart rate Effects of Isoproterenol occurred rapidly ( Fig. 1) and is termed the "early" Three doses of isoproterenol were administered. response, whereas the maximum increases in mean Threshold responses were observed with 0.01 /ig/kg, external left circumflex coronary diameter and CSA occurred later ( Fig. 1) and is termed the "late response." Since responses to isoproterenol (0.1 /xg/kg) (Table 1) and (0.5 jUg/kg) ( Table 2) were qualitatively similar, only the responses to one of the doses (0.1 jug/kg) will be presented in detail. Isoproterenol, 0.1 /ig/kg, during the early response reduced mean arterial pressure by 25 ± 2.2%, LV enddiastolic pressure by 30 ± 4.4%, and LDCR by 62 ± 3.9%, and increased heart rate (82 ± 10%), LV dP/dt (79 ± 12%), and mean coronary blood flow (85 ± 4.9%), while CSA rose slightly. The "late" response was characterized by smaller reductions in mean arterial pressure (7.4 ± 1.0%), LV end-diastolic pressure (12 ± 4%), and LDCR (25 ± 5.3%) and lesser increases in heart rate (24 ± 3.7%), LV dP/dt (12 ± 3.4%), and mean coronary blood flow (14 ± 2.1%). However, at this time, C5A rose by a maximum of 24 ± 2.4% above control. After selective /?i-adrenergic receptor blockade with atenolol (1.0 mg/kg), isoproterenol (0.1 jug/kg) during the early response elicited similar reductions in mean arterial pressure (19 ± 2.3%), but no longer increased LV dP/dt, and elicited significantly smaller increases in heart rate (25 ± 5.9%) ( Fig. 2 ) and mean coronary blood flow (39 ± 9.4%). LDCR fell less, when calculated as percent change (43 ± 4.8%) ( Fig.  3) but not as the absolute change (Table 1) . This difference might be attributed in part to differences in baseline levels of LDCR (Table 1) . Isoproterenol (0.1 /xg/kg) during the late response did not affect LV dP/dt or heart rate, and decreased mean arterial pressure (5.6 ± 1.2%), LDCR (17 ± 3.3%), and increased mean coronary blood flow (7.3 ± 1.7%), and CSA (9.0 ± 1.9%). The changes in LDCR, coronary blood flow and CSA were significant, F < 0.025, but significantly less, P < 0.025, than occurred prior to /?i-adrenergic receptor blockade. Again, the absolute change in LDCR was not significantly different, due to the difference in baseline (Table 1) .
In five dogs after combined atenolol (1.0 mg/kg) and atropine (0.1 mg/kg), isoproterenol (0.1 /tg/kg) did not increase heart rate and LV dP/dt, but still reduced mean arterial pressure (22 ± 2%) and increased CSA (8.7 ± 1.9%).
After combined /?i-and /?_<-adrenergic receptor blockades with propranolol, isoproterenol no longer induced significant effects. The effects of isoproterenol infusion were also studied in seven dogs before and after /3i-adrenergic receptor blockade and with heart rate held constant at a rapid rate (140 ± 3.3 beats/min) (Table 3 ). These results were qualitatively similar to those obtained with bolus isoproterenol administration. Specifically, while CSA rose by 17 ± 2.6% with isoproterenol infusion in dogs with spontaneous rhythm, after fiiadrenergic receptor blockade and with heart rate constant, isoproterenol infusion increased CSA significantly less, P < 0.01, by 6.3 ± 1.1%.
Effects of Pirbuterol (1.0 jug/kg) Pilot studies indicated that approximately 10-fold the dose of pirbuterol was required to elicit equidepressor effects to isoproterenol. Threshold responses were observed with pirbuterol, 0.1 jug/kg, iv. Accordingly a dose of 1.0 jug/kv, iv was studied in detail, for comparison with the effects of isoproterenol, 0.1 jug/ kg. The peak effects of pirbuterol on mean arterial pressure, coronary blood flow, LDCR, LV dP/dt, and heart rate also occurred rapidly, and are also termed the "early" response, whereas the maximum increases in mean external left circumflex coronary diamter, and CSA also occurred later and are also termed the "late response." Pirbuterol during the early response reduced mean arterial pressure by 24 ± 2.1%, LV end-diastolic pressure by 34 ± 4.6%, and LDCR by 54 ± 4.8%, and increased heart rate (73 ± 10%), LV dP/dt (51 ± 15%) and mean coronary blood flow (84 ± 7.1%), while CSA rose slightly. The "late" response was characterized by smaller reductions in mean arterial pressure (10 ± 1.5%), LV end-diastolic pressure (19 ± 5.1%), and LDCR (28 ± 5.0%) and lesser increases in heart rate (26 ± 3.3%), LV dP/dt (11 ± 3.9%), and mean coronary blood flow (31 ± 4.5%). However, at this time, CSA rose by a maximum of 21 ± 3.0% above control.
After selective /5i-adrenergic receptor blockade with atenolol (1.0 mg/kg), pirbuterol, during the early response, elicited similar reductions in mean arterial pressure (20 ± 1.9%), but no longer increased LV dP/ dt and elicited significantly smaller increases in heart rate (32 ± 7.3%) (Fig. 2) and mean coronary blood flow (49 ± 9.2%). LDCR fell less, when calculated as percent change (46 ± 4.7%) ( Fig. 3) but not as the absolute change. This difference might be attributed to differences in baseline levels of LDCR. Pirbuterol during the late response did not affect LV dP/dt or heart rate and decreased mean arterial pressure (7.6 ± 1.4%), LDCR (22 ± 2.2%) and increased mean coronary blood flow (15 ± 3.5%), and CSA (15 ± 61 2.8%). The changes in LDCR, coronary blood flow and CSA were significant, (P < 0.025), but significantly less (P < 0.025) than occurred prior to (i\adrenergic receptor blockade.
In five dogs after combined atenolol (1.0 mg/kg) and atropine (0.1 mg/kg), pirbuterol did not increase heart rate and LV dP/dt, but still reduced mean arterial pressure (22 ± 2.6%) and increased CSA (10 ± 1.0%).
After combined fi\-and /k-adrenergic receptor blockades with propranolol, pirbuterol no longer induced significant effects.
The effects of pirbuterol, 1.0 fig/kg, were qualitatively similar to those for isoproterenol, 0.1 jug/kg, (Figs. 2 and 3) . The responses to these two drugs were not significantly different either before or after /3iadrenergic receptor blockade. However, when the percent reduction in responses of coronary blood flow and CSA that were observed for isoproterenol and pirbuterol after selective /?i-adrenergic receptor blockade were compared, significantly greater atten- uation of the increases in coronary blood flow and CSA by /?i-adrenergic receptor blockade were observed with isoproterenol than with pirbuterol ( Fig.  4 ).
Effects of Prenalterol (4 /ig/kg per min X 5 min) (Figs. 2 and 3)
The data for prenalterol were evaluated during the peak effects of the drug, which occurred 5 minutes after cessation of infusion. Selective /Vadrenergic receptor stimulation with prenalterol did not affect mean arterial pressure, but increased heart rate by 40 ± 4.7%, LV dP/dt by 72 ± 9.6%, mean coronary blood flow by 34 ± 1 1 % and CSA by 26 ± 2.9%, and reduced LDCR by 29 ± 4.5%. In contrast to what was observed with isoproterenol, with prenalterol, increases in coronary diameter and blood flow occurred at the same time, and maximal effects were correlated with peak increases in heart rate and LV dP/dt (Fig. 5) . After /?i-adrenergic blockade with atenolol, prenalterol no longer induced significant effects (Table 4 ). (Fig. 6) Isoproterenol (0.1 jug/kg) increased (P < 0.01) coronary sinus O> content by 78 ± 16% from a control level of 3.2 ± 0.2 vol.%, and decreased (P < 0.01) A-V O:i difference by 20 ± 4.1% from control of 10.3 ± 0.8 vol.%. Pirbuterol (1.0 ^tg/kg) elicited similar effects. In contrast, prenalterol tended to reduce coronary sinus O^ content and widen A-V O-> difference. These responses of coronary sinus O2 content and A-V O2 difference to prenalterol were significantly different, P < 0.01, from those to either isoproterenol or pirbuterol.
Effects of /3-Adrenergic Receptor Stimulation on Arterial and Coronary Sinus O 2 Contents
After selective /?i-adrenergic receptor blockade, isoproterenol (0.1 jug/kg) and pirbuterol (1.0 jug/kg) still increased coronary sinus O_> content by 43 ± 8 and 41 ± 6%, respectively, and reduced A-V O> difference by 17 ± 5 and 21 ± 5%, respectively, for the two drugs.
Discussion
The effects of yS-adrenergic receptor stimulation have not been examined previously on direct and continous measurements of large coronary arterial dimensions in the intact animal. The lack of information is due most likely to the absence of appropriate measuring techniques. Most prior studies have relied upon measurements of coronary blood flow and arterial pressure and calculations of coronary vascular resistance. These measurements assess pri- . The advantages and limitations in this methodology have been discussed in detail previously Macho et al., 1981) . Utilizing this methodology in the current investigation, we examined the extent to which large and small coronary arteries respond to /?-adrenergic receptor stimulation. Effects on small coronary vessels were assessed by calculations of late 63 diastolic coronary vascular resistance, whereas effects on large coronary arteries were assessed by calculations of left circumflex coronary cross-sectional area. Isoproterenol increases myocardial Oj consumption and consequently dilates resistance coronary vessels on a metabolic basis. In addition, isoproterenol also dilates coronary vessels by its action on vascular /?-adrenergic receptors (Berne and Rubio, 1979; Parratt, 1980; Klocke et al., 1965; Zuberbuhler and Bohr, 1975) independent of changes in myocardial metabolic demands. Most prior studies conducted in openchest, anesthetized animals indicate that isoproterenol stimulation of vascular receptors in coronary resistance vessels is primarily (5> mediated, since it still occurs after selective /Vblockade (Ross and Jorgensen, 1970; Adam et al., 1970; McRaven et al., 1971; Mark et al., 1972; Gross and Feigl, 1975 ). An exception to this is the study by Lucchesi and Hodgeman (1971) observing blunted coronary vascular as well as myocardial inotropic responses to /S-adrenergic receptor stimulation after selective ySi-adrenergic receptor blockade. It is also important to note the considerable evidence, which superficially appears contradictory, from studies in isolated coronary vessels, which would suggest that isoproterenol stimulates /?i-adrenergic vascular receptors (Baron et al., 1972; Drew and Levy, 1972; Johannson, 1973; De La Lande et al., 1974) . Since the latter studies examined primarily large coronary arteries, and whereas studies in openchest anesthetized animals (Ross and Jorgensen, 1970; McRaven et al., 1971; Mark et al., 1972; Adam et al., 1970; Gross and Feigl, 1975) assessed primarily effects on smaller, coronary resistance vessels, it is conceivable that both points of view are correct. One other point must be considered in understanding differences between experiments conducted in isolated vessels and more intact preparations. Until recently, it has generally been accepted that acetylcholine constricts isolated vessel preparations (Furchgott, 1955) , but dilates coronary vessels in vivo (Levy and Zieske, 1969; Blesa and Ross, 1970) . Recently, Furchgott and Zawadzki (1980) noted that these differences could be attributed to manipulation of the endothelium in isolated vessel preparations. It is also conceivable that /?2-adrenergic vascular receptors are located on the endothelial surface of large coronary arteries, and can only be demonstrated on isolated vessel preparations if special care is taken not to disturb the endothelium.
As expected, in the present investigation, with /?,and /?2-adrenergic receptors intact, isoproterenol induced a substantial reduction in calculated coronary vascular resistance. The drug also increased large coronary arterial cross-sectional area, which occurred at a later time than the peak increase in coronary' blood flow, but still in the face of reduced arterial pressure. Since the decrease in pressure should have induced passive constriction of the large coronary vessels, as was observed when pressure was varied mechanically in the terminal experiments, the active dilation induced by isoproterenol was probably Isoproterenol Prenalterol Pirbuterol p<0.025 from Control slightly underestimated. The same reservation applies to the studies with pirbuterol. However, it is important to note that the comparisons made in this investigation, i.e., before and after y8i-adrenergic receptor blockade or between isoproterenol and pirbuterol, are not affected by changes in arterial pressure, since this parameter, although not constant, responded similarly under all these conditions. Another factor, which could have modulated large coronary arterial response, was that of reflex w-adrenergic activation. In this situation, as well, it is important to realize that the stimulus for a-adrenergic activation was similar, i.e., the decreases in arterial pressure were similar in the presence of both isoproterenol and pirbuterol, and in the presence and absence of /?i-adrenergic receptor blockade.
If the isoproterenol-induced vasodilation was due simply to /?2-adrenergic receptor stimulation, it should not have been affected by /?i-adrenergic receptor blockade. However, after selective /?i-adrenergic receptor blockade, isoproterenol induced similar reductions in arterial pressure (indicating that peripheral vascular /?2-adrenergic receptors were intact), but failed to increase LV dP/dt significantly (indicating that myocardial /?i-adrenergic receptors were essentially blocked). Under these conditions, isoproterenol elicited significantly less dilation of both small and large coronary arteries. To eliminate the potential contribution of the tachycardia secondary to vagal withdrawal, experiments were repeated in five dogs after combined /?i-adrenergic and cholinergic receptor blockades. Furthermore, in seven dogs with infusions of isoproterenol 0.1 /i.g/kg per min, heart rate was held constant after /?i-adrenergic receptor blockade. Under both these conditions, isoproterenol failed to increase heart rate as well as LV dP/dt, but still reduced arterial pressure and dilated large coronary arteries. The effects on large coronary arteries, while significant, were markedly less than observed in dogs when heart rate rose.
It is interesting that selective /?i-adrenergic receptor blockade blunted the dilation of large coronary arteries more effectively than that in resistance coronary vessels. In fact, whereas percent decreases in late diastolic coronary vascular resistance were less with isoproterenol after /?i-adrenergic receptor blockade, the actual changes were similar under both conditions. This discrepancy could be attributed to the change in baseline. However, while depressor responses to isoproterenol were similar before and after /? t -adrenergic receptor blockade, increases in mean coronary blood flow were markedly attenuated. The smaller increases in coronary blood flow with isoproterenol after fl\adrenergic receptor blockade probably reflects the reduced metabolic dilator stimuli, i.e., smaller increases in heart rate and no increases in myocardial contractility.
The results of these experiments are compatible with the hypothesis that isoproterenol induces dilation of large coronary arteries not only by stimulation of vascular /?2-adrenergic receptors, but conceivably also by direct stimulation of vascular /?i-adrenergic receptors. The results are also consistent with the hypothesis that regulation of large as well as small coronary arteries is secondary to changes in myocardial metabolism (Macho et al., 1981) .
In order to stimulate /?2-adrenergic receptors primarily, we administered pirbuterol (Moore et al., 1978) . Dose-response curves indicated that a 1.0 fig/ kg dose of pirbuterol elicited a reduction in arterial pressure equivalent to a 0.1 jug/kg dose of isoproterenol. We were surprised to find that the responses to pirbuterol and isoproterenol were so similar in terms of effect-not only on the coronary circulation, but, also, on LV dP/dt and heart rate. In part, the similarity between the two agents can be ascribed to secondary reflex effects on heart rate and myocardial contractility. However, it is also conceivable that pirbuterol is not a pure /?.>-adrenergic agonist. We examined this possibility in a series of experiments after reflex effects were eliminated by pretreating the dogs with chronic reserpine and atropine. Under those condi-tions, isoproterenol, 0.1 /xg/kg, and pirbuterol, 1.0/xg/ kg, still elicited similar reductions in mean arterial pressure, but significantly different effects on heart rate and LV dP/dt ( Table 5 ). Note that although pirbuterol's effects on heart rate and LV dP/dt were less than that of isoproterenol, the effects were substantial and statistically significant (Table 5) . Thus, the similarity in response of the two drugs can be ascribed to two factors: (1) both drugs elicited reflex effects, and (2) both drugs elicit qualitatively but not quantitatively similar effects on fi\-and /?_<-adrenergic receptors. In regard to the latter point, it is important to keep in mind that atenolol eliminated a significantly greater fraction of the responses to isoproterenol, as compared with pirbuterol on coronary crosssectional area and coronary blood flow (Fig. 4) .
In order to selectively stimulate ySi adrenergic receptors, prenalterol was administered. The selectivity of this agent in terms of stimulating /Si-adrenergic receptors in the conscious dog has been noted previously in our laboratory . Whereas it has been reported that prenalterol may exert other actions, e.g., /S 2 -adrenergic blocking effects under some experimental conditions (Wagner and Schumann, 1980; Hedberg et al., 1980) , it is important to note that we observed no effect of the drug after selective /?i-adrenergic blockade. Thus, any action of prenalterol, other than that of ySi-adrenergic receptor stimulation, is not of great importance under the conditions of the present experiments. In these experiments, prenalterol, by stimulating /?i-adrenergic receptors, increased heart rate and LV dP/dt. These changes occurred over a similar time course with the decreases in calculated late diastolic coronary vascular resistance and increases in large coronary arterial cross-sectional area. These experiments lend further support to the conclusion that the large coronary vessels dilate not only in response to /?2-adrenergic receptor stimulation, but also in response to either increases in myocardial metabolic demands (Macho et al., 1981) , or to direct stimulation of /?i-adrenergic vascular receptors (Baron et al., 1972; Drew and Levy, 1972; Johannson, 1973; De La Lande et al., 1974) .
To discern between primary vascular effects and effects secondary to changes in myocardial metabolism, coronary sinus O> content and A-V O> content differences were measured. As was observed previously by Klocke et al. (1965) , in the current experiments, isoproterenol in either the presence or absence of selective /?,-adrenergic receptor blockade induced excess coronary blood flow, increases in coronary sinus O> content, and reductions in A-V C\> difference. We observed similar responses with pirbuterol ( Fig. 6) . In contrast, prenalterol increased A-V O-> difference slightly. Thus, it is likely that the additional /?2-adrenergic receptor stimulation induced by isoproterenol or pirbuterol activated /^-vascular receptors and caused dilation of small and large coronary vessels independent of changes in myocardial O> demand. In contrast, the component of large vessel coronary dilation due to direct/?i-adrenergic receptor stimulation or secondary to /?i-adrenergic receptor stimulation of myocardial resistance vessels, was not of sufficient magnitude to elicit excess coronary blood flow, an increase in coronary sinus O-> content, and narrowing of A-V O> difference. The cellular mechanisms by which large coronary vessels could be regulated by changes in myocardial metabolic demands is not clear. One possibility is that adjacent myocardial cells liberate metabolities (e.g., adenosine) with increases in myocardial metabolic requirements, which then dilate coronary vessels. However, we have no data to support this conjecture. Regardless of the mechanism, it is important to recognize that the caliber of large coronary arteries varies in response to alterations in myocardial metabolic demands.
In summary, the results of the present investigation indicate an important role for regulation of large coronary arteries by ^-adrenergic mechanisms. While, in the normal heart, the contribution of large coronary arteries to total coronary vascular resistance is small, about 5% (Winbury, et al., 1969) , its role in the presence of myocardial ischemia, particularly due to partial occlusion of a large coronary artery, assumes greater significance where changes in large vessel caliber may be crucial in regulation of the flow to the ischemic area. (i\, as compared with /^-adrenergic receptor stimulation, appeared to exert more important effects on large coronary arteries. However, a role for /?2-adrenergic receptor stimulation was also demonstrated. It is conceivable that the /?j-adrenergic effects were secondary to changes in myocardial metabolism and not due to direct activation of specific /?i-vascular receptors. These conclusions must be tempered by the fact that these experiments were carried out with pharmacological activation of fi-adrenergic receptors. Thus, the role of /?-adrenergic receptor regulation of large coronary arteries by neural activation remains to be demonstrated.
